Pharvaris N.V. ( (PHVS) ) has released its Q3 earnings. Here is a breakdown of the information Pharvaris N.V. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
In its third quarter 2025 financial results, Pharvaris highlighted advancements in its clinical development programs, including the anticipated release of topline data from its pivotal Phase 3 RAPIDe-3 study for the on-demand treatment of HAE attacks by the end of 2025. The company also reported progress in the CHAPTER-3 study for prophylactic treatment, and the initiation of the CREAATE study for both prophylactic and on-demand treatment of AAE-C1INH attacks.
Key financial metrics from the third quarter reveal a strong liquidity position with cash and cash equivalents totaling €329 million as of September 30, 2025. Research and development expenses increased to €29.8 million, reflecting ongoing investment in clinical trials, while general and administrative expenses decreased to €9.8 million. The company reported a reduced quarterly loss of €37.1 million, compared to €41.7 million in the same period last year.
Pharvaris’ strategic focus remains on advancing its pipeline, with significant milestones expected in the coming quarters. The company is well-funded, with a cash runway extending into the first half of 2027, supporting its ongoing and future clinical trials.
Looking ahead, Pharvaris is poised to continue its development efforts, with upcoming data readouts from key studies potentially reinforcing its position in the treatment of bradykinin-mediated diseases. The management remains committed to delivering innovative therapies that combine efficacy with the convenience of oral administration.